Timeline
More in Pharma
Poolbeg activates first site for POLB 001 TOPICAL trial
"We believe POLB 001 has the potential to transform the cancer immunotherapy field through the prevention of CRS," said Jeremy Skillington, Chief Executive Officer
"We believe POLB 001 has the potential to transform the cancer immunotherapy field through the prevention of CRS," said Jeremy Skillington, Chief Executive Officer